REPORT ID 3015

United States Resistant Pseudomonas Aeruginosa Infections Drugs Market Report 2017

Publish Date
12-Dec-17
Pages
100
Format
Electronic (PDF)

In this report, the United States Resistant Pseudomonas Aeruginosa Infections Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Resistant Pseudomonas Aeruginosa Infections Drugs in these regions, from 2012 to 2022 (forecast).

United States Resistant Pseudomonas Aeruginosa Infections Drugs market competition by top manufacturers/players, with Resistant Pseudomonas Aeruginosa Infections Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    ContraFect Corp
    Inhibrx LP
    Achaogen Inc
    LegoChem Biosciences Inc
    Melinta Therapeutics Inc
    Novartis AG
    AmpliPhi Biosciences Corp
    Biolytics Pharma
    Shionogi & Co Ltd

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Semi-Synthetic Penicillin
    Cephalosporin
    Lactam Drugs
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Clinic
    Home Care

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Resistant Pseudomonas Aeruginosa Infections Drugs Market Report 2017
1 Resistant Pseudomonas Aeruginosa Infections Drugs Overview
    1.1 Product Overview and Scope of Resistant Pseudomonas Aeruginosa Infections Drugs
    1.2 Classification of Resistant Pseudomonas Aeruginosa Infections Drugs by Product Category
        1.2.1 United States Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Semi-Synthetic Penicillin
        1.2.4 Cephalosporin
        1.2.5 Lactam Drugs
        1.2.6 Others
    1.3 United States Resistant Pseudomonas Aeruginosa Infections Drugs Market by Application/End Users
        1.3.1 United States Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Home Care
    1.4 United States Resistant Pseudomonas Aeruginosa Infections Drugs Market by Region
        1.4.1 United States Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Resistant Pseudomonas Aeruginosa Infections Drugs Status and Prospect (2012-2022)
        1.4.3 Southwest Resistant Pseudomonas Aeruginosa Infections Drugs Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Resistant Pseudomonas Aeruginosa Infections Drugs Status and Prospect (2012-2022)
        1.4.5 New England Resistant Pseudomonas Aeruginosa Infections Drugs Status and Prospect (2012-2022)
        1.4.6 The South Resistant Pseudomonas Aeruginosa Infections Drugs Status and Prospect (2012-2022)
        1.4.7 The Midwest Resistant Pseudomonas Aeruginosa Infections Drugs Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Resistant Pseudomonas Aeruginosa Infections Drugs (2012-2022)
        1.5.1 United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2022)
        1.5.2 United States Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2022)

2 United States Resistant Pseudomonas Aeruginosa Infections Drugs Market Competition by Players/Suppliers
    2.1 United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Resistant Pseudomonas Aeruginosa Infections Drugs Average Price by Players/Suppliers (2012-2017)
    2.4 United States Resistant Pseudomonas Aeruginosa Infections Drugs Market Competitive Situation and Trends
        2.4.1 United States Resistant Pseudomonas Aeruginosa Infections Drugs Market Concentration Rate
        2.4.2 United States Resistant Pseudomonas Aeruginosa Infections Drugs Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Region (2012-2017)
    3.2 United States Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Region (2012-2017)
    3.3 United States Resistant Pseudomonas Aeruginosa Infections Drugs Price by Region (2012-2017)

4 United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Type (2012-2017)
    4.3 United States Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2012-2017)
    4.4 United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate by Type (2012-2017)

5 United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales (Volume) by Application (2012-2017)
    5.1 United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Application (2012-2017)
    5.2 United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Resistant Pseudomonas Aeruginosa Infections Drugs Players/Suppliers Profiles and Sales Data
    6.1 ContraFect Corp
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Inhibrx LP
        6.2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Achaogen Inc
        6.3.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 LegoChem Biosciences Inc
        6.4.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Melinta Therapeutics Inc
        6.5.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Novartis AG
        6.6.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 AmpliPhi Biosciences Corp
        6.7.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Biolytics Pharma
        6.8.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Shionogi & Co Ltd
        6.9.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview

7 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Cost Analysis
    7.1 Resistant Pseudomonas Aeruginosa Infections Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Resistant Pseudomonas Aeruginosa Infections Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Resistant Pseudomonas Aeruginosa Infections Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Resistant Pseudomonas Aeruginosa Infections Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Forecast by Type (2017-2022)
    11.3 United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Forecast by Application (2017-2022)
    11.4 United States Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer